SRNE News and Press, Sorrento Therapeutics Inc. From 12/06/21

Sorrento has received orders from its logistics partner and a large diagnostic laboratory client for official commercial launch of COVISTIX™ COVID-19 Virus Rapid Antigen Detection Test in Brazil. SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasd...

Scilex Holding Company, a subsidiary of Sorrento Therapeutics (SRNE +1.7%), announced the signing of a letter of intent with Vickers Vantage Corp. I (NASDAQ:VCKA) for a proposed business combination. Subject to adjustments, the deal values Scilex at ~$1.5B in terms of pre-transaction equity v...

Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Scilex of approximately $1...

Sorrento Therapeutics (NASDAQ:SRNE) announces the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for SARS-CoV-2 entry into host cells at Texas A&M University. Shares up 7.4% premarket&#...

A representative of novel M Pro inhibitor series, MPI8, dually inhibits M Pro and cathepsin L, a key viral entry enzyme, with high potency and selectivity. Other analogs of the series have been evaluated by Sorrento to develop an oral antiviral drug for treatment of patients i...

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: Evercore ISI 4th Annual HealthCONx Conference Wednesday, December 1,...

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases” (“Abivertinib Teaser&#...

Sorrento Therapeutics (SRNE +3.1%) announces that its subsidiary Sorrento Therapeutics Mexico has executed a contract with a leading distributor to sell and distribute as many as 5 million COVI-STIX tests in the local market. An antigen-based test for rapid detection of COVID-19, COVI-ST...

SAN DIEGO and MEXICO CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of up to 5 m...

When big money bets against a stock through short positions, that’s vital intelligence for your own investment decisions. Equally important is whether or not the company has the fundamentals to turn things around. Unfortunately, some very popular stocks have attracted worri...